NASDAQ:ICPT - Intercept Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $21.36
  • Forecasted Upside: 19.08 %
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$17.94
▼ -0.25 (-1.37%)

This chart shows the closing price for ICPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Intercept Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICPT

Analyst Price Target is $21.36
▲ +19.08% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Intercept Pharmaceuticals in the last 3 months. The average price target is $21.36, with a high forecast of $32.00 and a low forecast of $10.00. The average price target represents a 19.08% upside from the last price of $17.94.

This chart shows the closing price for ICPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 10 polled investment analysts is to hold stock in Intercept Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 13 hold ratings
  • 2 sell ratings
2/21/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 13 hold ratings
  • 2 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 9 hold ratings
  • 2 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 2 sell ratings
11/18/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 1 sell ratings
2/16/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 1 sell ratings
5/17/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
7/16/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
8/15/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2022CowenLower Price Target$22.00Low
8/8/2022HC WainwrightLower Price TargetNeutral$18.00 ➝ $16.00Low
8/4/2022Raymond JamesBoost Price TargetOutperform$23.00 ➝ $26.00N/A
7/8/2022SVB LeerinkLower Price TargetMarket Perform$27.00 ➝ $21.00N/A
7/8/2022Needham & Company LLCLower Price TargetBuy$25.00 ➝ $22.00N/A
5/10/2022B. RileyBoost Price Target$30.00 ➝ $32.00Low
5/9/2022Raymond JamesLower Price Target$44.00 ➝ $23.00Medium
3/8/2022Canaccord Genuity GroupLower Price TargetHold$31.00 ➝ $29.00Low
3/3/2022Royal Bank of CanadaLower Price TargetSector Perform$22.00 ➝ $16.00High
3/3/2022Needham & Company LLCLower Price TargetBuy$30.00 ➝ $25.00Medium
3/3/2022SVB LeerinkLower Price TargetMarket Perform$30.00 ➝ $27.00Medium
1/10/2022B. RileyUpgradeNeutral ➝ Buy$25.00 ➝ $30.00High
11/8/2021BMO Capital MarketsReiterated RatingHold$22.00Low
11/5/2021Jefferies Financial GroupReiterated RatingHold$19.00Medium
11/4/2021B. RileyBoost Price TargetNeutral$22.00 ➝ $25.00High
11/4/2021Raymond JamesBoost Price TargetOutperform$40.00 ➝ $44.00Medium
8/20/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$17.00 ➝ $10.00Low
8/3/2021B. RileyBoost Price TargetNeutral$18.00 ➝ $22.00High
8/2/2021WedbushLower Price TargetOutperform$74.00 ➝ $67.00Low
8/2/2021HC WainwrightReiterated RatingNeutral$21.00 ➝ $18.00Low
8/1/2021Robert W. BairdReiterated RatingBuy$52.00Low
7/30/2021Royal Bank of CanadaBoost Price TargetSector Perform$22.00 ➝ $23.00Low
5/31/2021SVB LeerinkReiterated RatingHoldLow
5/27/2021JMP SecuritiesReiterated RatingHoldLow
5/25/2021B. RileyDowngradeBuy ➝ Neutral$65.00 ➝ $18.00High
5/10/2021OppenheimerLower Price Target$33.00 ➝ $20.00Medium
5/7/2021The Goldman Sachs GroupLower Price TargetNeutral$29.00 ➝ $18.00Medium
5/7/2021Raymond JamesLower Price TargetOutperform$52.00 ➝ $40.00Low
5/7/2021BMO Capital MarketsLower Price TargetMarket Perform$29.00 ➝ $19.00Low
5/7/2021Cantor FitzgeraldLower Price TargetNeutral$45.00 ➝ $23.00Low
5/6/2021Stifel NicolausLower Price TargetHold$29.00 ➝ $16.00Low
3/12/2021HC WainwrightUpgradeSell ➝ Neutral$25.00 ➝ $21.00Medium
3/2/2021Needham & Company LLCLower Price TargetBuy$80.00 ➝ $34.00Medium
3/1/2021WedbushLower Price TargetOutperform$106.00 ➝ $88.00Low
3/1/2021B. RileyLower Price TargetBuy$74.00 ➝ $65.00Low
3/1/2021HC WainwrightReiterated RatingNeutral ➝ Sell$25.00Low
3/1/2021Chardan CapitalLower Price TargetBuy$58.00 ➝ $45.00Low
2/26/2021Raymond JamesLower Price TargetOutperform$60.00 ➝ $52.00High
2/23/2021HC WainwrightDowngradeNeutral ➝ Sell$25.00Low
1/19/2021WedbushLower Price TargetOutperform$116.00 ➝ $106.00Low
1/15/2021Bank of AmericaDowngradeNeutral ➝ Underperform$40.00 ➝ $27.00High
12/21/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$30.00Low
11/20/2020B. RileyLower Price TargetBuy$97.00 ➝ $74.00High
11/10/2020BMO Capital MarketsLower Price TargetMarket Perform$56.00 ➝ $38.00High
11/10/2020Royal Bank of CanadaLower Price TargetSector Perform$49.00 ➝ $40.00High
11/10/2020Credit Suisse GroupLower Price TargetHold ➝ Neutral$60.00 ➝ $42.00High
11/10/2020Robert W. BairdUpgradeNeutral ➝ Outperform$52.00High
11/10/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$60.00High
11/10/2020SVB LeerinkLower Price TargetMarket Perform$50.00 ➝ $48.00High
11/10/2020Chardan CapitalLower Price TargetBuy$105.00 ➝ $58.00High
8/28/2020WedbushReiterated RatingBuy$140.00Medium
8/11/2020Royal Bank of CanadaReiterated RatingHold$57.00Low
8/11/2020OppenheimerReiterated RatingHold$54.00Medium
8/11/2020Chardan CapitalReiterated RatingBuy$105.00Medium
8/10/2020Needham & Company LLCInitiated CoverageBuy$100.00Medium
8/10/2020B. RileyReiterated RatingBuy$97.00Medium
8/10/2020Stifel NicolausBoost Price TargetHold$51.00 ➝ $56.00High
7/30/2020Piper SandlerInitiated CoverageOverweight$82.00Medium
7/21/2020JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
6/30/2020Chardan CapitalReiterated RatingBuy$105.00Low
6/30/2020CitigroupUpgradeNeutral ➝ Buy$110.00 ➝ $67.00High
6/30/2020SVB LeerinkLower Price TargetMarket Perform$89.00 ➝ $50.00Low
6/30/2020Needham & Company LLCLower Price TargetBuy$150.00 ➝ $100.00Low
6/30/2020UBS GroupDowngradeBuy ➝ Neutral$135.00 ➝ $57.00Medium
6/30/2020Robert W. BairdDowngradeOutperform ➝ Neutral$52.00Medium
6/30/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$57.00Medium
6/29/2020B. RileyReiterated RatingBuy$97.00Medium
6/29/2020WedbushReiterated RatingBuy$140.00Medium
6/29/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$137.00 ➝ $59.00Medium
6/29/2020CowenDowngradeOutperform ➝ Market Perform$149.00 ➝ $47.00Medium
6/29/2020Raymond JamesDowngradeOutperform ➝ Market PerformHigh
6/29/2020Stifel NicolausLower Price TargetHold$100.00 ➝ $51.00High
6/29/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$150.00 ➝ $60.00High
6/29/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$107.00 ➝ $52.00High
6/29/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$117.00 ➝ $55.00Medium
6/29/2020OppenheimerDowngradeOutperform ➝ Market Perform$124.00 ➝ $46.00High
6/29/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$146.00 ➝ $46.00High
6/25/2020HC WainwrightInitiated CoverageNeutral$92.00Medium
6/4/2020BMO Capital MarketsInitiated CoverageOutperform$107.00Low
5/22/2020Robert W. BairdReiterated RatingBuy$227.00High
5/22/2020B. RileyReiterated RatingBuy$158.00N/A
5/22/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$145.00 ➝ $115.00High
5/14/2020WedbushReiterated RatingBuy$257.00Medium
5/13/2020B. RileyReiterated RatingBuy$158.00High
5/12/2020Chardan CapitalReiterated RatingBuy$145.00High
5/12/2020Stifel NicolausLower Price TargetHold$100.00 ➝ $99.00Medium
5/12/2020CitigroupDowngradeBuy ➝ Neutral$110.00Medium
5/11/2020Needham & Company LLCReiterated RatingBuy$150.00High
4/27/2020WedbushReiterated RatingBuy$257.00High
4/8/2020Royal Bank of CanadaReiterated RatingBuy$117.00High
4/2/2020Chardan CapitalInitiated CoverageBuy$145.00Low
3/26/2020WedbushReiterated RatingBuy$257.00High
3/26/2020B. RileyReiterated RatingBuy$158.00High
3/5/2020Bank of AmericaInitiated CoverageNeutral$111.00Low
2/27/2020WedbushReiterated RatingBuy$257.00High
2/26/2020Cantor FitzgeraldReiterated RatingBuy$186.00High
2/26/2020OppenheimerLower Price Target$146.00 ➝ $124.00Low
2/26/2020CitigroupUpgradeNeutral ➝ Buy$140.00 ➝ $125.00High
2/20/2020B. RileyReiterated RatingBuy$158.00N/A
2/10/2020WedbushReiterated RatingBuy$257.00Medium
1/29/2020WedbushReiterated RatingBuy$257.00Low
1/22/2020WedbushReiterated RatingBuy$257.00Medium
1/9/2020B. RileyBoost Price TargetBuy$133.00 ➝ $158.00Low
1/2/2020SVB LeerinkReiterated RatingUnderperformMedium
1/2/2020CitigroupDowngradeBuy ➝ Neutral$85.00 ➝ $140.00High
12/18/2019WedbushReiterated RatingBuy$257.00Low
12/17/2019Robert W. BairdReiterated RatingBuy$227.00Low
12/17/2019Needham & Company LLCReiterated RatingBuy$150.00Low
12/17/2019Credit Suisse GroupReiterated RatingOutperform$87.00 ➝ $141.00Low
12/17/2019Wells Fargo & CompanyReiterated RatingPositive ➝ Overweight$120.00 ➝ $146.00Low
12/13/2019B. RileyReiterated RatingBuy$133.00High
11/25/2019Robert W. BairdReiterated RatingBuy$227.00High
11/25/2019Stifel NicolausBoost Price Target$86.00 ➝ $102.00High
11/5/2019WedbushReiterated RatingBuy$243.00High
11/5/2019Needham & Company LLCReiterated RatingBuy$150.00Low
10/21/2019Raymond JamesLower Price TargetStrong-Buy$148.00 ➝ $147.00High
10/18/2019Jefferies Financial GroupSet Price TargetBuy$125.00High
10/18/2019Credit Suisse GroupLower Price Target$167.00 ➝ $87.00Low
9/30/2019WedbushSet Price TargetBuy$243.00Low
9/6/2019Royal Bank of CanadaSet Price TargetBuy$135.00Medium
9/4/2019CitigroupUpgradeNeutral ➝ Buy$106.00 ➝ $85.00Medium
8/23/2019Raymond JamesSet Price TargetBuy$148.00N/A
8/12/2019Stifel NicolausReiterated RatingHold$86.00Low
8/8/2019Royal Bank of CanadaReiterated RatingBuy$135.00Medium
8/8/2019Cantor FitzgeraldLower Price TargetOverweight$191.00 ➝ $186.00High
8/7/2019Raymond JamesSet Price TargetBuy$149.00Medium
8/6/2019OppenheimerLower Price TargetOutperform$170.00 ➝ $160.00Medium
7/5/2019WedbushSet Price TargetBuy$243.00Low
6/24/2019Stifel NicolausInitiated CoverageHold ➝ Hold$89.00 ➝ $89.00Medium
6/6/2019Raymond JamesReiterated RatingBuyLow
5/13/2019WedbushReiterated RatingOutperform$251.00 ➝ $243.00Medium
5/8/2019CowenReiterated RatingBuy$149.00Medium
5/8/2019B. RileyReiterated RatingBuy ➝ Buy$169.00Medium
5/2/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$90.02Medium
4/29/2019OppenheimerLower Price Target$175.00 ➝ $170.00Medium
4/12/2019B. RileySet Price TargetBuy$169.00High
4/12/2019WedbushSet Price TargetBuy$251.00High
4/12/2019Wells Fargo & CompanyBoost Price TargetMarket Perform$99.00 ➝ $104.00High
3/28/2019UBS GroupBoost Price TargetBuy$139.00Low
3/27/2019WedbushReiterated RatingBuy$251.00Low
3/19/2019OppenheimerReiterated RatingBuyLow
3/5/2019WedbushSet Price TargetBuy$251.00Medium
3/1/2019Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$130.00High
2/28/2019B. RileyReiterated RatingBuy ➝ Buy$155.00 ➝ $169.00High
2/28/2019Raymond JamesSet Price TargetStrong-Buy ➝ Buy$184.00 ➝ $187.00High
2/28/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$170.00 ➝ $191.00High
2/21/2019CitigroupBoost Price TargetNeutral ➝ Neutral$106.00 ➝ $140.00High
2/20/2019OppenheimerBoost Price TargetOutperform$140.00 ➝ $175.00High
2/20/2019Royal Bank of CanadaBoost Price TargetSector Perform$137.00High
2/20/2019JMP SecuritiesBoost Price TargetOutperform ➝ In-Line$175.00 ➝ $200.00High
2/19/2019WedbushBoost Price TargetOutperform ➝ Outperform$220.00 ➝ $248.00High
2/19/2019Wells Fargo & CompanyBoost Price TargetMarket Perform$75.00 ➝ $127.00High
2/19/2019Cantor FitzgeraldReiterated RatingBuy$170.00High
2/15/2019Bank of AmericaReiterated RatingUnderperform$68.00Low
2/14/2019Raymond JamesReiterated RatingBuyLow
2/12/2019Credit Suisse GroupReiterated RatingOutperformHigh
2/4/2019Raymond JamesUpgradeOutperform ➝ Strong-Buy$184.00Low
1/31/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$167.00High
1/30/2019JMP SecuritiesUpgradeMarket Perform ➝ Outperform$75.00 ➝ $175.00High
1/28/2019Jefferies Financial GroupBoost Price TargetBuy$150.00Low
1/24/2019Needham & Company LLCUpgradeHold ➝ Buy$150.00High
1/23/2019UBS GroupInitiated CoverageBuy ➝ Buy$130.00Low
1/14/2019LaidlawUpgradeHold ➝ Buy$99.00 ➝ $130.00Low
12/11/2018B. RileyInitiated CoverageBuy ➝ Buy$155.00 ➝ $155.00High
12/6/2018Cantor FitzgeraldReiterated RatingBuy$170.00Low
11/19/2018CIBCUpgradeMarket Perform ➝ OutperformMedium
11/19/2018OppenheimerUpgradeMarket Perform ➝ Outperform$140.00Medium
11/19/2018UBS GroupUpgradeMarket Perform ➝ OutperformMedium
11/6/2018WedbushSet Price TargetBuy$220.00High
10/31/2018OppenheimerSet Price TargetHold$100.00High
10/31/2018Needham & Company LLCReiterated RatingHoldHigh
10/8/2018OppenheimerSet Price TargetHold$100.00High
10/2/2018Raymond JamesDowngradeStrong-Buy ➝ Outperform$126.00 ➝ $141.00High
10/1/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$170.00Medium
9/12/2018Roth CapitalInitiated CoverageBuy ➝ Buy$192.00Low
8/15/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$244.00High
8/12/2018WedbushSet Price TargetBuy$217.00Medium
8/6/2018WedbushBoost Price TargetOutperform ➝ Outperform$203.00 ➝ $217.00High
8/6/2018The Goldman Sachs GroupUpgradeSell ➝ Buy$46.00 ➝ $157.00High
8/3/2018WedbushReiterated RatingBuy$217.00 ➝ $203.00Low
8/3/2018LaidlawDowngradeBuy ➝ Hold$90.00 ➝ $95.00Medium
8/3/2018Royal Bank of CanadaReiterated RatingBuy$115.00High
8/2/2018Needham & Company LLCReiterated RatingHoldMedium
8/2/2018OppenheimerSet Price TargetHold$100.00High
8/2/2018Cantor FitzgeraldSet Price TargetHold$69.00High
7/17/2018OppenheimerSet Price TargetHold$100.00Low
6/28/2018Raymond JamesInitiated CoverageStrong-Buy$122.00High
5/18/2018WedbushReiterated RatingBuyMedium
5/11/2018WedbushReiterated RatingBuy$203.00Medium
5/9/2018CowenReiterated RatingBuy$88.00Low
5/8/2018OppenheimerReiterated RatingHoldHigh
5/8/2018Cantor FitzgeraldReiterated RatingHold$58.00Low
4/17/2018WedbushLower Price TargetOutperform ➝ Outperform$203.00 ➝ $256.00Low
3/28/2018Needham & Company LLCReiterated RatingHoldMedium
3/20/2018OppenheimerReiterated RatingHoldLow
3/9/2018WedbushReiterated RatingOutperform$256.00 ➝ $253.00High
2/15/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$152.00 ➝ $155.00High
2/15/2018OppenheimerReiterated RatingHoldHigh
2/14/2018Cantor FitzgeraldSet Price TargetHold$58.00High
2/13/2018Wells Fargo & CompanyReiterated RatingMarket Perform$62.00 ➝ $57.00Medium
2/12/2018Deutsche Bank AktiengesellschaftInitiated CoverageBuy$103.00Medium
2/7/2018The Goldman Sachs GroupDowngradeNeutral ➝ SellLow
1/29/2018OppenheimerReiterated RatingHoldMedium
1/25/2018Robert W. BairdReiterated RatingOutperform$332.00 ➝ $253.00Low
1/22/2018Credit Suisse GroupSet Price TargetBuy$201.00 ➝ $167.00High
1/5/2018WedbushReiterated RatingBuy$253.00Low
12/29/2017CitigroupSet Price TargetHold$74.00High
12/22/2017WedbushReiterated RatingBuy$253.00High
12/21/2017CitigroupSet Price TargetHold$74.00Low
12/12/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy$106.00High
11/28/2017SVB LeerinkReiterated RatingHold$60.00Low
11/20/2017WedbushReiterated RatingBuy$253.00N/A
11/1/2017Needham & Company LLCReiterated RatingHoldN/A
11/1/2017CowenReiterated RatingBuy$112.00N/A
11/1/2017Cantor FitzgeraldUpgradeUnderweight ➝ Neutral$69.00N/A
11/1/2017LaidlawUpgradeHold ➝ Buy$90.00N/A
10/24/2017OppenheimerReiterated RatingHoldN/A
10/13/2017Bank of AmericaLower Price TargetUnderperform$102.00 ➝ $73.00N/A
10/6/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$79.00N/A
10/4/2017Royal Bank of CanadaReiterated RatingOutperform ➝ OutperformHigh
10/4/2017JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
9/26/2017JMP SecuritiesReiterated RatingOutperform$150.00 ➝ $140.00Medium
9/26/2017Credit Suisse GroupReiterated RatingOutperform$201.00Low
9/26/2017Jefferies Financial GroupReiterated RatingBuy$275.00 ➝ $135.00Low
9/26/2017Needham & Company LLCReiterated RatingHoldLow
9/26/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$200.00 ➝ $244.00Medium
9/23/2017Robert W. BairdReiterated RatingOutperform$332.00Low
9/23/2017SVB LeerinkLower Price TargetMarket Perform$120.00 ➝ $66.00Low
9/22/2017UBS GroupDowngradeOutperform ➝ Market PerformLow
9/22/2017OppenheimerReiterated RatingOutperform ➝ HoldHigh
9/22/2017BMO Capital MarketsReiterated RatingOutperform$221.00 ➝ $160.00High
9/22/2017Morgan StanleyReiterated RatingUnderweight$75.00 ➝ $50.00High
9/22/2017CowenReiterated RatingBuy$232.00 ➝ $112.00High
9/22/2017LaidlawLower Price TargetHold ➝ Hold$118.00 ➝ $90.00High
9/22/2017CitigroupDowngradeBuy ➝ Neutral$150.00 ➝ $92.00High
9/21/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$265.00 ➝ $95.00High
9/20/2017Jefferies Financial GroupReiterated RatingBuy$275.00High
9/19/2017CitigroupReiterated RatingBuy ➝ Neutral$150.00Medium
9/15/2017WedbushReiterated RatingOurperform$253.00Low
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$244.00High
9/14/2017OppenheimerReiterated RatingOutperform$200.00Medium
9/14/2017CowenReiterated RatingOutperform$232.00Medium
9/13/2017BMO Capital MarketsReiterated RatingOutperform$221.00High
9/13/2017Robert W. BairdReiterated RatingOutperform$332.00High
9/13/2017Jefferies Financial GroupReiterated RatingBuy$275.00High
9/13/2017Cantor FitzgeraldReiterated RatingUnderweight$69.00High
9/13/2017Wells Fargo & CompanyReiterated RatingOutperformHigh
8/25/2017WedbushReiterated RatingOutperform$253.00Low
(Data available from 8/16/2017 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/17/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/16/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/18/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/17/2022
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/17/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/16/2022
  • 6 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/16/2022
  • 1 very positive mentions
  • 12 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
8/15/2022

Current Sentiment

  • 1 very positive mentions
  • 12 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Intercept Pharmaceuticals logo
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
Read More

Today's Range

Now: $17.94
Low: $17.65
High: $18.00

50 Day Range

MA: $14.15
Low: $11.23
High: $18.19

52 Week Range

Now: $17.94
Low: $10.81
High: $20.50

Volume

20,748 shs

Average Volume

901,131 shs

Market Capitalization

$534.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Intercept Pharmaceuticals?

The following Wall Street analysts have issued reports on Intercept Pharmaceuticals in the last twelve months: B. Riley, BMO Capital Markets, Canaccord Genuity Group Inc., Cowen Inc., HC Wainwright, Jefferies Financial Group Inc., Needham & Company LLC, Raymond James, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ICPT.

What is the current price target for Intercept Pharmaceuticals?

11 Wall Street analysts have set twelve-month price targets for Intercept Pharmaceuticals in the last year. Their average twelve-month price target is $21.36, suggesting a possible upside of 17.4%. B. Riley has the highest price target set, predicting ICPT will reach $32.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $10.00 for Intercept Pharmaceuticals in the next year.
View the latest price targets for ICPT.

What is the current consensus analyst rating for Intercept Pharmaceuticals?

Intercept Pharmaceuticals currently has 1 sell rating, 6 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ICPT, but not buy more shares or sell existing shares.
View the latest ratings for ICPT.

What other companies compete with Intercept Pharmaceuticals?

How do I contact Intercept Pharmaceuticals' investor relations team?

Intercept Pharmaceuticals' physical mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company's listed phone number is (646) 747-1000 and its investor relations email address is [email protected] The official website for Intercept Pharmaceuticals is www.interceptpharma.com. Learn More about contacing Intercept Pharmaceuticals investor relations.